SGMO

Sangamo Therapeutics Inc

SGMO, USA

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.

https://www.sangamo.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SGMO
stock
SGMO

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Hold" by Analysts MarketBeat

Read more →
SGMO
stock
SGMO

What drives SGMO stock price - Support Zone Identification & The Smart Money Is Buying These Picks earlytimes.in

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$3.25

Analyst Picks

Strong Buy

3

Buy

2

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

21.93

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-559.51 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-39.41 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-4,916.01 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

13.20

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 22.20% of the total shares of Sangamo Therapeutics Inc

1.

Vanguard Group Inc

(3.1072%)

since

2025/06/30

2.

Wasatch Advisors LP

(2.6795%)

since

2025/06/30

3.

Renaissance Technologies Corp

(2.2669%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(1.9409%)

since

2025/07/31

5.

Wasatch Ultra Growth

(1.8541%)

since

2025/06/30

6.

BlackRock Inc

(1.5938%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7834%)

since

2025/07/31

8.

Geode Capital Management, LLC

(0.773%)

since

2025/06/30

9.

GSA Capital Partners LLP

(0.7442%)

since

2025/06/30

10.

Charles Schwab Investment Management Inc

(0.4248%)

since

2025/06/30

11.

Ikarian Capital, LLC

(0.4177%)

since

2025/06/30

12.

UBS Group AG

(0.414%)

since

2025/06/30

13.

Two Sigma Advisers, LLC

(0.4%)

since

2025/06/30

14.

Fidelity Extended Market Index

(0.3847%)

since

2025/07/31

15.

Schwab US Small-Cap ETFâ„¢

(0.3551%)

since

2025/08/30

16.

Two Sigma Investments LLC

(0.2907%)

since

2025/06/30

17.

Jacobs Levy Equity Management, Inc.

(0.2806%)

since

2025/06/30

18.

State Street Corp

(0.2772%)

since

2025/06/30

19.

Susquehanna International Group, LLP

(0.2563%)

since

2025/06/30

20.

HighTower Advisors, LLC

(0.2468%)

since

2025/06/30

21.

Amvescap Plc.

(0.2255%)

since

2025/06/30

22.

BlackRock Advantage Small Cap Core Instl

(0.208%)

since

2025/07/31

23.

Squarepoint Ops LLC

(0.2072%)

since

2025/06/30

24.

Invesco RAFI US 1500 Small-Mid ETF

(0.1946%)

since

2025/08/29

25.

FMR Inc

(0.193%)

since

2025/06/30

26.

Morgan Stanley - Brokerage Accounts

(0.1898%)

since

2025/06/30

27.

Royal Bank of Canada

(0.1729%)

since

2025/06/30

28.

Extended Equity Market Fund K

(0.1355%)

since

2025/06/30

29.

Fidelity Total Market Index

(0.1338%)

since

2025/07/31

30.

Macquarie Healthcare I

(0.1326%)

since

2025/07/31

31.

Renaissance Global Small Cap

(0.124%)

since

2025/05/31

32.

Fidelity Series Total Market Index

(0.1138%)

since

2025/07/31

33.

iShares Core S&P Total US Stock Mkt ETF

(0.1025%)

since

2025/08/31

34.

Wasatch Long Short Alpha Composite

(0.0927%)

since

2025/03/31

35.

Wasatch Long/Short Alpha Institutional

(0.0927%)

since

2025/06/30

36.

Spartan Extended Market Index Pool F

(0.086%)

since

2025/07/31

37.

Blackrock Russell 2000 Alpha Tilts Fd A

(0.0854%)

since

2025/06/30

38.

Fidelity VIP Disciplined Small Cap Init

(0.0729%)

since

2025/06/30

39.

NT Ext Equity Mkt Idx Fd - L

(0.0721%)

since

2025/06/30

40.

Northern Trust Extended Eq Market Idx

(0.0721%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.11

EPS Estimate

0.0002

EPS Difference

-0.1102

Surprise Percent

-55100%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.